{"name":"Allergy and Asthma Center of El Paso","slug":"allergy-and-asthma-center-of-el-paso","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Symbicort 160/4.5 pMDI","genericName":"Symbicort 160/4.5 pMDI","slug":"symbicort-160-4-5-pmdi","indication":"Asthma maintenance treatment","status":"marketed"},{"name":"Advair HFA MDI 115/21","genericName":"Advair HFA MDI 115/21","slug":"advair-hfa-mdi-115-21","indication":"Asthma maintenance therapy","status":"marketed"}]}],"pipeline":[{"name":"Symbicort 160/4.5 pMDI","genericName":"Symbicort 160/4.5 pMDI","slug":"symbicort-160-4-5-pmdi","phase":"marketed","mechanism":"Symbicort combines an inhaled corticosteroid (budesonide) and a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and dilate airways.","indications":["Asthma maintenance treatment","Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"Advair HFA MDI 115/21","genericName":"Advair HFA MDI 115/21","slug":"advair-hfa-mdi-115-21","phase":"marketed","mechanism":"Advair HFA combines fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5DeWhFUUh3Sk1YZnN4aGpwdVg1enRtM3MzU1VFVlBMMkZBd1hjWHpMbmRlTk5ldXRyZUVvVTNGQnRzVmg0TVprZHotRGlqR2VCZGVibEJTOThRUXdrR1dFaEsza1VKWXd1UGVpXzl2Vno4RkNh?oc=5","date":"2025-02-20","type":"deal","source":"Private Equity Stakeholder Project PESP","summary":"Private Equity Healthcare Deals: 2024 in Review - Private Equity Stakeholder Project PESP","headline":"Private Equity Healthcare Deals: 2024 in Review","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}